KR890005277A - Diagnosis and Treatment of Double-stranded RNA Deficiency Status - Google Patents

Diagnosis and Treatment of Double-stranded RNA Deficiency Status Download PDF

Info

Publication number
KR890005277A
KR890005277A KR1019880011423A KR880011423A KR890005277A KR 890005277 A KR890005277 A KR 890005277A KR 1019880011423 A KR1019880011423 A KR 1019880011423A KR 880011423 A KR880011423 A KR 880011423A KR 890005277 A KR890005277 A KR 890005277A
Authority
KR
South Korea
Prior art keywords
dsrna
mismatched
amount
administered
deficiency
Prior art date
Application number
KR1019880011423A
Other languages
Korean (ko)
Inventor
에이.카터 윌리엄
Original Assignee
원본미기재
헴 리서치 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 헴 리서치 인코오포레이티드 filed Critical 원본미기재
Publication of KR890005277A publication Critical patent/KR890005277A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes

Abstract

내용 없음No content

Description

2본쇄 RNA 부족 상태의 진단 및 치료방법Diagnosis and Treatment of Double-stranded RNA Deficiency Status

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

제1도는 숙주질병에 대한 이중 경로 및 숙주 회복에 대한 경로를 설명하고 있는 개요도이다.1 is a schematic diagram illustrating the dual pathway for host disease and the pathway for host recovery.

제2A도는 일정량의 IFN치료 시작전후 여러날 동안 신세 타제 활성을 조사한 그래프이다.Figure 2A is a graph of synthetase activity for several days before and after the start of a certain amount of IFN treatment.

제2B도는 치료 120일 후의 백혈구 세포수와 잘못 짝지워진 dsRNA의 양을 비교한 그래프이다.Figure 2B is a graph comparing the amount of dsRNA mismatched with the white blood cell count after 120 days of treatment.

제3도는 각각의 트랙을 따라 나타난 여러 영역 및 여러가지 밴드를 나타내고 있는 폴리아크릴 아미드 겔 전기영동 플레이트의 사진이다.3 is a photograph of a polyacrylamide gel electrophoretic plate showing various regions and various bands along each track.

Claims (24)

환자에서 dsRNA 결핍상태를 진단하며, 결핍 상태일때 dsRNA를 대치하며 상기 결핍상태를 교정하기에 충분한 양의 외생 dsRNA를 투여함을 특징으로 하는 방법.Diagnosing a dsRNA deficiency in a patient, wherein the deficit is replaced with a dsRNA and administered with an amount of exogenous dsRNA sufficient to correct the deficiency. 제1항에 있어서, dsRNA 결핍 상태가 면역 장애, 비루스 감염 또는 비조절된 암세포 증식에 의한 것을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA deficient state is due to an immune disorder, viral infection, or unregulated cancer cell proliferation. 제2항에 있어서, 원인 비루스가 레트로비루스, 파라믹코비루스, 리노비루스 또는 헤르페스 비루스족인 것을 특징으로 하는 방법.3. The method according to claim 2, wherein the causative virus is retrovirus, paramycovirus, linobius or herpes virus. 제1항에 있어서, dsRNA 결핍 상태가 면역개의 성분 세포 내에 존재하며 그 성분 세포 가증식 또는 분화 과정에 있거나 또는 그 과정에 있지 않는 것을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA deficient state is present in component cells of the immune dog and is or is not in the process of proliferating or differentiating the component cells. 제1항에 있어서, dsRNA 결핍의 추정 진단이 적절한 양 또는 생리학적양으로 제공되는 림포킨의 주입에 대하여 비루스 암 또는 면역 장애의 초기 비반응 또는 부분 반응에 기초하는 것을 특징으로 하는 방법.The method of claim 1, wherein the presumptive diagnosis of dsRNA deficiency is based on an initial non-response or partial response of virus cancer or an immune disorder to infusion of lymphokines provided in an appropriate amount or physiological amount. 제5항에 있어서, 추정 진단이 2-5A 경로 중간 물질의 생화학적 측정 또는 숙주 방어에 포함되며, 천연 dsRNA에 의해 부분적으로 또는 전체적으로 조절되는 것으로 나타나는 기타 다른 생화학적 경로의 측정에 의해 확증되는 것을 특징으로 하는 방법.The method according to claim 5, wherein the putative diagnosis is included in the biochemical measurement or host defense of the 2-5A pathway intermediate and confirmed by the measurement of other biochemical pathways that appear to be partially or totally regulated by native dsRNA. How to feature. 제1항에 있어서, 건강한 사람에게서, 기대될 수 있는 농도의 천연 dsRNA의 자극하기에 충분한 양의 합성 dsRNA를 주입한후, 어떤 dsRNA중개된 경로에서 양성의 변화를 관찰하거나 또는 상기 주입결과로서 임상학적 상태의 변수를 측정함을 특징으로 하는 방법.The method of claim 1, wherein, in a healthy person, after injecting a sufficient amount of synthetic dsRNA to stimulate the expected concentration of native dsRNA, observe a positive change in any dsRNA mediated pathway or as a result of the infusion. Measuring the variables of the biological state. 제1항에 있어서, dsRNA 대치 요법이 정합된 dsRNA로 실시됨을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA replacement therapy is performed with matched dsRNA. 제1항에 있어서, dsRNA 대치 요법이 부정합된 dsRNA로 실시됨을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA replacement therapy is performed with mismatched dsRNAs. 제9항에 있어서, dsRNA가 5 우라실 또는 구아니딘 염기의 1에서 부터 30의 1까지 함유하는 폴리이노시네이트와 폴리시티딜레이트의 복합물인 것을 특징으로 하는 방법.10. The method of claim 9, wherein the dsRNA is a complex of polyinosinate and polycytidylate containing from 1 to 30 of 5 uracil or guanidine base. 제9항에 있어서, 부정합 dsRNA가 rIn·(C11-14)n인 것을 특징으로 하는 방법.The method of claim 9, wherein the mismatched dsRNA is rI n. (C 11-14 ) n . 제9항에 있어서, dsRNA는 결합 파손의 부분을 함유하며 rIn·(C11-14)n의 양호한 치료적 바율 특성을 나타내는 것을 특징으로 하는 방법.10. The method of claim 9, wherein the dsRNA contains a portion of the bond breakage and exhibits good therapeutic rate properties of rI n. (C 11-14 ) n . 제9항에 있어서, dsRNA가 인체의 일차 생체액의 1ml 당 1 내지 1,000ug의 dsRNA의 수준을 유도하며, 인체의 이차 또는 간질액에서 dsRNA-유도 중개체 물질들의 균형적 양들을 유도하는 양으로 투여됨을 특징으로 하는 방법.The method of claim 9, wherein the dsRNA induces a level of 1 to 1,000 ug of dsRNA per ml of human body's primary biological fluid, and in an amount that induces balanced amounts of dsRNA-inducing mediator substances in the human secondary or interstitial fluid. Administered. 인체의 침해된 조직에 외생 dsRNA를 공급하고 세포내 dsRNA 수준을 복구시키는 것을 특징으로 하여 세포내 병원체가 함께 존재하여, dsRNA가 결핍되어 발생된 인체의 조직 병상을 경감시키는 방법.Supplying exogenous dsRNA to the injured tissue of the human body and restoring intracellular dsRNA levels, thereby coexisting with intracellular pathogens, thereby alleviating tissue lesions of the human body caused by dsRNA deficiency. 제14항에 있어서, 세포내 병원체가 비루스이거나 또는 비조절 증식의 암세포인 것을 특징으로 하는 방법.The method of claim 14, wherein the intracellular pathogen is a virus or a cancer cell of unregulated proliferation. 제15항에 있어서, 비루스 병원체가 레트로비루스, 파라믹코비루스, 리노비루스 또는 헤르페스족 비루스인 것을 특징으로 하는 방법.16. The method of claim 15, wherein the viral pathogen is retrovirus, paramycovirus, linobius or herpes virus. 제14항에 있어서, 조직 병상이 모든 면역계의 성분에 존재하며, 그 성분 세포는 증식 또는 분화중에 있거나 또는 증식 또는 분화중에 있지 않을 수 있는 것을 특징으로 하는 방법.The method of claim 14, wherein the tissue condition is present in all components of the immune system, and the component cells may or may not be in the process of proliferation or differentiation. 제5항에 있어서, 림포킨이 외생 dsRNA와 함께 투여됨을 특징으로 하는 방법.The method of claim 5, wherein the lymphokin is administered with an exogenous dsRNA. 제1항에 있어서, dsRNA 대치 요법이 정합 dsRNA로 실시됨을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA replacement therapy is performed with matched dsRNA. 제1항에 있어서, dsRNA 대치 요법이 부정합 dsRNA로 실시됨을 특징으로 하는 방법.The method of claim 1, wherein the dsRNA replacement therapy is performed with mismatched dsRNA. 제9항에 있어서, 부정합 dsRNA가 5 우라실 또는 구아니딘 염기의 1에서부터 30에서 1까지 함유하는 폴리이노시아네이트와 폴리시티딜레이트의 복합물인것을 특징으로 하는 방법.10. The method of claim 9, wherein the mismatched dsRNA is a complex of polyinocyanate and polycytidylate containing from 1 to 30 to 1 of 5 uracil or guanidine base. 제9항에 있어서, 부정합 dsRNA가 rIn·(C11-14)n인 것을 특징으로 하는 방법.The method of claim 9, wherein the mismatched dsRNA is rI n. (C 11-14 ) n . 제9항에 있어서, dsRNA가 결합 파손 부분을 함유하며, rIn·(C11-14)n의 양호한 치료학적 비율 특성을 나타냄을 특징으로 하는 방법.10. The method of claim 9, wherein the dsRNA contains a binding breakage moiety and exhibits good therapeutic ratio properties of rI n. (C 11-14 ) n . 제9항에 있어서, 부정합 dsRNA를 인체의 일차 생체액의 1ml 당 1 내지 1,000ug의 dsRNA 수준을 유도하며 인체의 이차 또는 간질액에서 dsRNA-유도 중개체 물질의 균형적 양들을 유도하는 양으로 투여함을 특징으로 하는 방법.10. The method of claim 9, wherein the mismatched dsRNA is administered in an amount that induces a dsRNA level of 1 to 1,000 ug per ml of human body's primary biological fluid and induces balanced amounts of dsRNA-inducing mediator material in the human secondary or interstitial fluid. Characterized in that. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880011423A 1987-09-04 1988-09-03 Diagnosis and Treatment of Double-stranded RNA Deficiency Status KR890005277A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9352387A 1987-09-04 1987-09-04
US093,523 1987-09-04

Publications (1)

Publication Number Publication Date
KR890005277A true KR890005277A (en) 1989-05-13

Family

ID=22239406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880011423A KR890005277A (en) 1987-09-04 1988-09-03 Diagnosis and Treatment of Double-stranded RNA Deficiency Status

Country Status (15)

Country Link
JP (1) JPH0825884B2 (en)
KR (1) KR890005277A (en)
CN (1) CN1031651A (en)
AU (3) AU2186488A (en)
CA (1) CA1336683C (en)
DK (1) DK491088A (en)
FI (1) FI884069A (en)
IL (1) IL87664A (en)
NO (1) NO883868L (en)
NZ (1) NZ226033A (en)
OA (1) OA08911A (en)
PH (1) PH26320A (en)
PT (1) PT88415B (en)
RU (1) RU2001917C1 (en)
ZA (1) ZA886581B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088344C (en) * 1997-10-17 2002-07-31 青岛市卫生防疫站 Process for preparing selenium or zinc enriched earthworm dry powder or extract
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
JPS57200310A (en) * 1981-05-26 1982-12-08 Merck & Co Inc Local application of interferon inducer
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles

Also Published As

Publication number Publication date
JPH0825884B2 (en) 1996-03-13
AU2186488A (en) 1989-03-09
NO883868D0 (en) 1988-08-30
PT88415B (en) 1992-10-30
NZ226033A (en) 1999-08-30
JPH01131118A (en) 1989-05-24
RU2001917C1 (en) 1993-10-30
PT88415A (en) 1989-07-31
AU1001495A (en) 1995-03-30
NO883868L (en) 1989-03-06
IL87664A0 (en) 1989-02-28
IL87664A (en) 1995-03-15
CN1031651A (en) 1989-03-15
ZA886581B (en) 1989-04-26
DK491088A (en) 1989-03-05
CA1336683C (en) 1995-08-15
FI884069A0 (en) 1988-09-02
FI884069A (en) 1989-03-05
OA08911A (en) 1989-10-31
AU1736692A (en) 1992-07-30
PH26320A (en) 1992-04-29
DK491088D0 (en) 1988-09-02

Similar Documents

Publication Publication Date Title
Rudge et al. Encephalomyelitis in primary hypogammaglobulinaemia
Lightfoote et al. Lead intoxication in an adult caused by Chinese herbal medication
JPH04243830A (en) Uridine used for curing pharmacologically peripheral complication of diabetes
Robinson et al. Regulation of granulopoiesis: positive feed-back
Rutkove An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a
Glass et al. Oral treatment of pernicious anemia with small doses of vitamin B12 combined with mucinous materials derived from the hog stomach
KR890005277A (en) Diagnosis and Treatment of Double-stranded RNA Deficiency Status
KR20100024019A (en) Multi-purpose food concentrate mineral preparation and preparation method thereof
Furmanski BAL therapy of severe peripheral neuropathies
Gilles et al. Studies on the Significance of High Serum Gamma-Globulin Concentrations in Gambian Africans: III.—Gamma-Globulin Concentrations of Gambian Women Protected from Malaria for Two Years
Shoenfeld et al. Carbamazepine(Tegretol)-induced thrombocytopenia.
David et al. Typhoid fever: unusual presentation
WO2004064767A2 (en) Nitric oxide inducing agents
KR101130617B1 (en) A funtional drink containing multifuntional mineral complex
RU2196576C1 (en) Method of treatment of patients with hemorrhagic fever and renal syndrome
Gargour et al. Anterior radiculopathy and lupus erythematosus cells: report of case
Skårberg et al. Oxymetholone Treatment in Hypoproliferative Anaemia1: I. Frequency of Response
Malone et al. Blood grouping on blotting-paper
Naveen et al. COMPARATIVE RESEARCH STUDY ON BIOCHEMICAL ANALYSIS OF UNPURIFIED AND PURIFIED MIRUTHAR SINGI (LEAD SULPHIDE)
Cope Endocrinology And Nutrition
WO1996040038A2 (en) Treatment of anemia with procaine compositions
RU1780752C (en) Method of immunotherapy
Gambill et al. Effect of intravenous administration of nicotinic acid on blood bilirubin
Levkovitz et al. Leukocytosis related to the therapeutic dosage of sulpiride
Ito et al. A Hæmagglutination Phenomenon between Tanned Erythrocytes and Sera of Guinea Pigs

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application